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Abstract
Elucidating the DNA repair pathways that are activated in the presence of genotoxic agents is critical 
to understand their modes of action. Although the DT40 cell-based DNA damage response (DDR) 
assay provides rapid and sensitive results, the assay cannot be used on genotoxic compounds 
that require metabolic activation to be reactive. Here, we applied the metabolic activation system 
to a DDR and micronucleus (MN) assays in DT40 cells. Cyclophosphamide (CP), a well-known 
cross-linking agent requiring metabolic activation, was preincubated with liver S9 fractions. When 
DT40 cells and mutant cells were exposed to the preactivated CP, CP caused increased cytotoxicity 
in FANC-, RAD9-, REV3- and RAD18-mutant cells compared to isogenic wild-type cells. We then 
performed a MN assay on DT40 cells treated with preactivated CP. An increase in the MN was 
observed in REV3- and FANC-mutant cells at lower concentrations of activated CP than in the 
parental DT40 cells. These results demonstrated that the incorporation of metabolic preactivation 
system using S9 fractions significantly potentiates DDR caused by CP in DT40 cells and their 
mutants. In addition, our data suggest that the metabolic preactivation system for DDR and MN 
assays has a potential to increase the relevance of this assay to screening various compounds for 
potential genotoxicity.
Introduction
Every year, a large number of new chemicals are added to the already 
vast Toxic Substances Control Act Inventory. A number of conven-
tional genotoxicity assays, such as the in vitro gene mutations test in 
bacteria, the in vitro test for chromosomal damage and/or gene muta-
tions in cultured mammalian cells and the in vivo test for cytoge-
netic effects in rodent bone marrow cells, have played an important 
role in identifying hazardous chemicals. However, the US National 
Research Council (NRC) committee suggested that a more modern 
approach be considered for toxicity testing in the 21st century (1). 
The overall toxicity testing framework developed by the commit-
tee focuses on four major components: chemical characterisation, 
toxicity pathways and targeted testing, dose–response and extrapo-
lation modelling and population-based and human exposure data. 
With regards to the conventional genotoxicity assays, little attention 
has been paid to the dose–response pattern and toxicity pathways 
activated by genotoxic agents. Recently, a mechanistic understand-
ing and quantitative analysis of genotoxic agents were highlighted in 
order to determine acceptable exposure levels in humans (2–6). The 
use of a comprehensive set of in vitro tests to identify the pathways 
affected in the presence of genotoxic agents would provide much 
stronger, mechanistically based, predictive tools for human health 
risk assessment.
For this purpose, the US Tox21 program adopted a DNA dam-
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that broadly probed biological targets, pathways and mechanisms 
in relation to genotoxicity and/or cytotoxicity endpoints for a large 
number of chemicals (7,8). The reverse genetic approach provides a 
powerful method for studying gene function and regulation. DT40 
cells originated from a chicken B-lymphocyte line derived from an 
avian leucosis virus-induced bursal lymphoma isolated in 1985 (9). 
We established a multiwell-plate-based method that makes use of the 
DT40 isogenic cell line and its dozens of available mutants knocked 
out in DNA repair and cell cycle pathways (10–12). This assay, 
which is based on increased cytotoxicity in DNA repair-deficient 
DT40 mutants versus the parental DT40 cells, is a rapid and simple 
method to evaluate the genotoxicity of xenobiotics and is suitable 
for high throughput screening (8).
In order to screen a broader range of chemicals, the current 
DT40 cell-based DDR assay needs to incorporate metabolic activa-
tion because some xenobiotics show genotoxic potential only after 
metabolic activation. In this study, we applied a metabolic activation 
system using S9 to the DT40 cell-based DDR assay. We first utilised a 
cell-washing method for the metabolic activation system. The wash-
ing method is an established procedure for metabolic activation in 
the genotoxicity study; however, this process may introduce physi-
cal stress to the cells from centrifugation and loss of cells by media 
change. In particular, DT40 cells are very sensitive to various envi-
ronmental stressors, such as pipetting pressure and temperature (11); 
therefore, it is better to avoid unnecessary stress derived from wash-
ing, centrifugation and handling errors. Furthermore, the washing 
method is not practical to screen for many chemicals particularly in 
the high-throughput format. We decided to incorporate the S9 meta-
bolic activation system using a convenient method that requires only 
the addition of the reagents in the DT40 cell-based DDR analysis. 
Consequently, DT40 cells need to be cultivated in the presence of S9 
fractions. However, cytochrome P450 metabolises lipids that make 
up S9 microsomes and result in the formation of toxic microsomal 
lipid peroxides (13,14). It is also known that cytochrome P450, in 
the absence of substrates, cycle electrons and could produce reactive 
oxygen species (15). Using preincubation method, we investigated 
the ability of cyclophosphamide (CP), a genotoxin requiring meta-
bolic activation (16), to induce differential cytotoxicity across the 
different DNA repair-deficient DT40 cell lines.
Materials and methods
DT40 cell culture and maintenance
Fetal bovine serum (FBS) and penicillin/streptomycin were obtained 
from Atlanta Biologicals (Norcross, GA, USA) and Sigma-Aldrich 
(St. Louis, MO, USA), respectively. RPMI 1640 culture medium 
(+glutamine, –phenol red) and chicken serum (CS) were acquired 
from Life Technologies (Grand Island, NY, USA). FBS and CS 
were heat inactivated at 56°C for 30 min. DT40 cells were main-
tained as described in our previous report (11). The list of twenty 
DT40 isogenic mutants used in this study is shown in Table 1 and 
Supplementary Table 1 is available at Mutagenesis Online, in which 
specific DNA repair pathways are knocked out.
Chemicals
Cyclophosphamide (CP), 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-
5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT), 
1-methoxy-5-methylphenazinium methyl sulfate (PMS) and 
dimethylsulfoxide (DMSO) were obtained from Sigma. The Aroclor 
1254-induced male rat liver S9, G-6-P, NADP Regensys™ B and 
MgCl2/KCl solution were purchased from MOLTOX (Boone, NC, 
USA). Dulbecco’s phosphate-buffered saline (PBS) was obtained from 
Life Technologies (Grand Island, NY, USA). CP was dissolved in PBS, 
and XTT cocktail was prepared with 500 mg of the XTT salt, 10.2 mg 
PMS and 3.3 ml DMSO. The S9 mixture was prepared prior to use 
following the manufacturer’s instructions and stored on ice until use.
DT40 cell-based DDR assay with metabolic 
activation
For the DDR assay, ~1200 cells were seeded in each well of a 96-well 
plate in 75 μl of medium. These plates were kept in an incubator at 
39.5°C until the start of treatment. Cells were exposed to S9, CP or a 
CP-S9 mixture, with a slight modification of our previously reported 
version of the assay (11). To determine the cytotoxic concentration of 
S9, cells were incubated with 0.052–0.25% S9 as a final concentra-
tion. The S9 was mixed with cofactor (0.4 mol/l MgCl2, 1.65 mol/l 
KCl, 1 mol/l glucose 6-phosphate and 0.5 mol/l NADPH in 0.1 mol/l 
phosphate buffer) to make a 10% mixture, and this mixture was 
diluted with PBS. To further optimise S9 incorporation into the DDR 
assay, two different methods were examined. The first method was a 
cell-washing method, in which cells were treated with CP in the pres-
ence of 1% S9 for 2 h. After treatment, plates were centrifuged (200g, 
5 min), cells were washed twice with fresh medium to remove the 
chemical and S9, and plates were incubated for 2–3 days to obtain 
a sufficient number of cells for the XTT assay. The second method 
was a preincubation method, in which the mixture of CP and 1% 
S9 was preincubated at 37°C for 30 min, and 8.35  µl of the reac-
tion mixture was transferred to the 96-well plate in which 75 μl of 
the cell suspension was seeded to set the final concentration of S9 at 
0.1%. A preliminary test to find the optimal dose was conducted in 
DT40 wild-type cells to select the appropriate concentration range 
that includes at least one concentration showing severe cytotoxicity 
and no cytotoxicity at lower concentrations. To observe the cytotoxic 
effect of CP without metabolic activation, cells were treated with CP 
without S9 on the same plate. Duplicate wells for each concentration 
of CP and four untreated wells as controls and four as blanks were set 
up (Figure 1A). In both methods, PBS was used as a negative control. 
Once treated or washed, cells were incubated for at least 48 h after 
which they were observed microscopically to determine the growth 
of the cells. Once the control cells were nearly contiguous, cells were 
exposed to the XTT cocktail. The plates were returned to the incuba-
tor until the dye developed sufficient colour for detecting absorbance 
on the plate reader, which normally takes 4–5 h. Absorbance was 
measured at 450 nm with a reference of 620 nm using a Tecan Sunrise 
(Tecan Systems, San Jose, CA, USA) plate reader with XFluorTM soft-
ware (Tecan, version 6.4). All data are reported as the means ± stand-
ard deviation of experiments done at least in triplicate.
Table 1. A list of examined DT40 mutant cell lines
DNA repair/tolerance pathway Genes
Base excision repair (BER) POLβ, FEN1, PARP1




Homologous recombination (HR) RAD54
Fanconi anaemia pathway (FANC) FANCD2, FANCI, FANCG, 
FANCC, FANCL, BRCA2
DNA damage checkpoint (DDC) RAD9, ATM
Mis-match repair (MMR) MSH3
Trans-lesion synthesis (TLS) REV3, POLη, POLκ, POLθ, 
RAD18
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Micronucleus frequency
For the micronucleus (MN) assay, flow cytometry-based MN meas-
urements were performed using an In Vitro MicroFlow™ Kit (Litron 
Laboratories, Rochester, NY, USA) according to the manufacturer’s 
instructions (17). Briefly, 150  µl of DT40 cells adjusted at 2 × 105 
cells/ml was seeded into 96-well plates at 39°C and 5% CO2 in a 
humid atmosphere. In a separate plate, the mixture of CP and 1% 
S9 was preincubated at 37°C for 30 min, which is the same pro-
cedure used in the DDR assay, and 16.7 µl of CP-S9 mixture was 
transferred to the 96-well plate to set the final concentration of S9 
at 0.1%. Cells were cultured at 39°C for 16 h, which corresponds to 
approximately two cell cycles. After treatment, the plate was cen-
trifuged (200g, 5 min) to collect cells, and the treatment medium 
was discarded. The plate was then placed on ice and incubated for 
20 min, and 50 μl of nucleic acid dye A working solution was added 
to each well. A  light source was placed ~15 cm above the samples 
for 30 min. Subsequently, the samples were washed once with cold 
1× buffer solution. Next, 100 μl of complete lysis solution 1 (includ-
ing nucleic acid dye B) was added to each well, and the samples 
were incubated for 1 h in the dark at 37°C. Subsequently, 100 μl of 
complete lysis solution 2 (including nucleic acid dye B) was added 
to each well, and the samples were incubated for 30 min in the dark 
at room temperature.
Samples for the MN assay were analyzed by flow cytometry (LSRII, 
BD Biosciences), using an excitation wavelength of 488 nm. The fre-
quency of MN was determined by acquiring at least 10 000 gated 
Figure 1. A 96-well plate format for treatment and cell survival in DT40 cells treated with CP and S9 using the washing method. (A) 96-well plate format for 
treatment. Cells were exposed to CP in duplicate wells with or without S9. Eight concentrations of CP and PBS as a control [C] was added to corresponding cell 
lines. The outside 2 wells were used as blank controls [B], and the average absorbance was subtracted from each well in the XTT analysis. (B) In the cell washing 
method, DT40 cells were treated with CP in the presence or absence of 1% S9 for 2 h, and cells were washed with medium and further incubated at 39°C for 
2–3 days. After the incubation, cell survival was examined in the XTT assay. Two independent experiments were conducted and the mean relative survival at 
each concentration was plotted. 
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nuclei per sample. The data are summarised as a mean of two or more 
independent experiments. The extent of survival in the treated cultures, 
described as relative population doubling (RPD), was evaluated as the 
reduction in population doubling (PD) (18), as compared to the vehicle 
control. The RPD was calculated using the following formula.
(Number of PD in treated cultures)/(Number of PD in 
control cultures) × 100,
where PD is defined as
[log(post-treatment cell number/initial cell number)]/log 2.
Data and statistical analysis
We calculated the lethal concentration 50 (LC50) values for each cell 
line using Graphpad Prism 5 (La Jolla, CA, USA). Based on the wild-
type LC50, the two-sided 95% confidence interval was calculated to 
judge whether the LC50 in mutant cells are biologically significant. In 
order to represent the point of departure (PoD) values for concentra-
tion–response in the MN assay, benchmark dose (BMD) values (US 
EPA/100/R-12/001 2012) were obtained using the EPA BMD soft-
ware v 2.5. These values represent a one standard deviation depar-
ture from control values, and the BMDL refers to the corresponding 
lower limit of a one-sided 95% confidence interval on the BMD. 
A log10 (concentration+0.5) was used to avoid taking logarithms of 
zero control values. In each instance, the best fitting result from Hill, 
exponential and polynominal response non-constant variance mod-
els was used. Additionally, Fisher’s exact test was performed to eval-
uate the statistical significance in MN frequency in the MN assay.
Results
Cell toxicity caused by CP in the presence of S9 
(washing method)
The S9 microsomal fraction of rat liver homogenate is widely used in 
the conventional in vitro genotoxicity assay to evaluate the toxicity of 
reactive metabolites. A final concentration of 1% S9 is the concentra-
tion typically used that maintains sufficient activity of S9 to generate 
genotoxic metabolites, as per the guidelines (19,20). We first utilised a 
cell washing method in parental DT40 cells. DT40 cells were exposed 
to CP in the presence of 1% S9 for 2 h. On the same plate, cells were 
exposed to CP in the absence of S9. CP with S9 caused cell toxicity in 
DT40 cells in a concentration-dependent manner (Figure 1B).
Assessment of S9 cytotoxicity in DT40 cells
Considering the toxicity of S9, the concentration of S9 was first 
adjusted in the cytotoxicity assay in order to minimise damage to 
DT40 cells. To determine the cytotoxic concentration of S9 in DT40 
cells during the incubation period, cells were incubated for 2–3 days 
in the presence of serially diluted S9 (Experiment I in Figure 2A). This 
exposure period allows cells to grow sufficiently for the XTT assay. As 
expected, the relative survival decreased as S9 concentration increased 
(Figure 2B). At a final concentration of 0.2% S9, almost no cells sur-
vived, while at 0.1% S9 no cytotoxicity was observed. Considering 
this steep cytotoxicity pattern and variability between experiments, 
we set the S9 concentration at 0.1% in the subsequent experiments.
Cell toxicity caused by preactivated CP using S9 
(preincubation method)
To minimise S9 fraction-derived cytotoxicity in DT40 cells but still 
maintain sufficient metabolic activity, DT40 cells were exposed to 
preactivated CP in the presence of S9 (Experiment II in Figure 2A). 
To determine the metabolic capacity of S9 after a variety of prein-
cubation times with S9, CP was incubated in the presence of 1% 
S9 for 10, 20, 30, 40 and 50 min, and the CP-S9 mixture was then 
exposed to DT40 cells by adding 1/9 volume of the CP-S9 preincuba-
tion mixture. The plots in Figure 2C show that the cytotoxicity of 
CP increases in a time-dependent manner. The survival curve after 
50 min of incubation was comparable to that of the washing meth-
ods. The LC50 dropped sharply within 30 min of incubation, and 
it continued to drop moderately until 50 min of incubation. These 
results also indicate that the metabolite of CP is stable for ~50 min. 
Because a small difference in LC50 was noted at incubation periods 
of 30 min or longer, CP was preincubated with S9 for 30 min in the 
DDR assay using a variety of DT40 mutants.
DDR assay using a panel of DT40 mutants treated 
with CP
To address whether the DT40 cell-based DDR assay incorporating 
metabolic activation can elucidate the repair mechanism of CP, 20 
isogenic DT40 mutant cell lines were exposed to the CP-S9 mixture 
after 30 min preincubation at 37°C. The LC50 in each mutant was 
compared to the concurrent LC50 in DT40 cells. The LC50 in paren-
tal DT40 cells was 5.19 ± 2.11 µM in eight independent assays. The 
calculated 95% confidence interval was 3.43–6.95 µM, which cor-
respond to 66–134% in relative LC50. For the mutant cell lines, the 
means of three or more independent experiments are plotted as the 
relative LC50. The mutant cell lines cover a variety of DNA repair/
tolerance pathways (e.g. BER, base excision repair; NER, nucleotide 
excision repair; FANC, Fanconi anaemia pathway; HR, homologous 
recombination; NHEJ, non-homologous end-joining; DDC, DNA 
damage checkpoint; MMR, mismatch repair; TLS, translesion DNA 
synthesis) (Supplementary Table 1, available at Mutagenesis Online). 
Among these cell lines, DT40 cells deficient in FANC genes showed 
marked hypersensitivity to activated CP, mainly due to interstrand 
DNA cross-links (Figure 3 and Supplementary Figure 1, available at 
Mutagenesis Online). They were ~10-fold or more sensitive to acti-
vated CP than DT40 wild-type cells (relative LC50 was less than 10% 
of DT40 cells) while no cytotoxicity was observed at the LC50 in the 
absence of metabolic activation both in DT40 wild-type and mutant 
cells (Supplementary Figure 1, available at Mutagenesis Online). In 
addition, severe toxicity (relative LC50 was less than 40% of DT40 
cells) was observed in the RAD9-, RAD18- and REV3-deficient 
DT40 cell lines, suggesting DDC, and TLS pathways are involved in 
the DDR to activated CP.
MN induction in DT40 and mutant cells treated with 
CP in the presence of S9
Because CP is a well-known genotoxic agent that induces MN forma-
tion in mammalian cells (21,22), the DT40 wild-type cells and some 
of the mutant cell lines hypersensitive to CP were exposed to CP after 
preincubation in the presence of S9, and the induced MN levels were 
determined. The RPD was also examined based on the cell numbers 
after the treatment. While activated CP induced MN in DT40 wild-
type and all mutant cell lines tested in this study (Figure 4), a significant 
increase in the MN frequency was observed at lower concentrations in 
REV3- and FANCG- and FANCD2-deficient cell lines than wild-type 
cells. The calculated PoD was 0.099, 0.110 and 0.027 µM in REV3, 
FANCG and FANCD2 cells, respectively, as compared to 0.176 µM in 
DT40 wild-type cells. At the highest concentration, FANCD2-deficient 
cells showed hypersensitivity to the CP-S9 mixture while REV3- and 
FANCG-deficient cells showed ~50% cytotoxicity.
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Figure 2. Experimental procedure and cell survival results in DT40 cells treated with either S9 alone or CP plus S9 using the preincubation method. (A) In 
Experiment I, wild-type cells were exposed to S9 alone at concentrations ranging from 0.052 to 0.25% as a final concentration to determine the non-cytotoxic 
concentration of S9 for the DDR assay. In Experiment II, 1% S9 and and different concentrations of CP were first preincubated for 10–50 min. The mixture 
solution was transferred to each well to expose to the wild-type cells. The final concentration of S9 was 0.1% for all wells. (B) To examine S9-mediated toxicity, 
DT40 cells were treated with S9 alone at different concentrations. DT40 cells were incubated with serially diluted S9. After 2–3 days, XTT was added and the 
absorbance measured by a plate reader to assess cell survival. Results show an average of five independent experiments. (C) Cell survival was measured in 
DT40 cells treated with CP and S9 using the preincubation method. Prior to cell treatment, CP was preincubated with 1% S9 for 10, 20, 30, 40, and 50 min. These 
preincubated mixtures were then exposed to DT40 cells by addition of 1/9 volume of the preincubation mixture to each well, and survival was examined using 
the XTT assay. The CP toxicity in the washing method was similar to toxicity caused by the 30- to 50-min preincubation method. The data shows the mean of 
two independent experiments.
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Discussion
In this study, we demonstrated that the incorporation of metabolic 
preactivation system using S9 fractions significantly potentiates 
DDR caused by CP in DT40 cells and their mutants using Aroclor 
1254-induced rat liver S9 fractions. Previously, we reported a multi-
well plate-based DDR assay using DT40 mutant cell lines that can be 
used as a high-throughput genotoxicity assay to characterise mech-
anisms of action of various compounds (10–12). While this assay 
is both rapid and sensitive, it is not applicable for genotoxic com-
pounds requiring metabolic activation. Incorporation of metabolic 
activation is mandatory in regular genotoxicity testing according to 
OECD guidelines (19,20). Here, we expanded the capability of the 
assay by incorporating metabolic activation. In this study, CP pre-
incubated with S9 and the resulting mixture, including metabolites, 
was mixed with the cell suspension at a ratio of 1:9 so that the final 
concentrations of S9 were non-toxic for the entire incubation period. 
This process prevents suspension cells from undergoing stress by 
centrifugation and loss of cells by medium change, which is routinely 
conducted for the conventional genotoxicity assays. The LC50 levels 
obtained from the washing and preincubation methods were almost 
comparable (Figure 2C), indicating our methods can generate suf-
ficient amounts of metabolites. Although many genotoxic chemicals 
other than CP need to be tested, we believe that this convenient pre-
incubation method could substitute the cell washing method used in 
the conventional genotoxicity assays in mammalian cells. Recently, 
the in vitro MN assay has also been conducted in a multi-well plate 
format using a washing method (23). Thus, our S9 preincubation 
method for the MN assay would be more suitable, require less time 
and resources, and reduce handling errors.
When cells were exposed to the CP-S9 mixture after 10- to 
50-min preincubation periods, DT40 cells showed a time-dependent 
decrease in LC50 after 50 min. While the LC50 dropped sharply within 
30 min, it continued to drop moderately between 30 and 50 min. 
Figure 3. DT40 cell-based DNA damage response assay for CP. Each mutant cell line lacking a specific gene was exposed to the CP-S9 mixture, and the relative 
LC50 was normalised based on the LC50 in DT40 wild-type cells. The data shows the mean of at least three independent experiments. The calculated 95% 
confidence interval in wild-type cells was 3.43 to 6.95 µM, which correspond to 66–134% in relative LC50. Mutants with average LC50s higher or lower than the 
95% confidence interval in wild-type cells were shown in the gray bar. See Table 1 for the abbreviation of the DNA repair/tolerance pathway.
Figure 4. Micronucleus induction in DT40 mutants treated with the CP-S9 mixture. MN induction and cytotoxicity in DT40 wild, REV3, FANCG and FANCD2 
mutants treated with CP-S9 mixture for 16 h is shown. The bar chart represents the MN frequency (%) in at least 10 000 main nuclei. The average control values 
were 0.35, 1.48, 0.83 and 0.95% in wild-type, REV3, FANCG and FANCD2 cells, respectively. Fisher’s exact test was used for statistical analysis. *P < 0.05; **P < 0.01. 
The circles represent the level of survival of each mutant cells evaluated by relative population doubling. These are the mean of two independent experiments.







utage/article-abstract/30/6/821/2622764 by guest on 20 July 2020
This suggests that S9 activity becomes gradually depleted, the metab-
olites could be partly degraded, or most of the CP was metabolically 
activated within 30 min. Taking these points into consideration, cells 
were exposed to the CP-S9 mixture after a 30-min preincubation 
period in our study.
The exceptional advantage of the DDR assay is the ability to elu-
cidate DNA repair or tolerance pathways, which helps to understand 
the mechanism of action of any chemical of interest. Due to technical 
complexity, genotoxic agents requiring metabolic activation, including 
CP, have rarely or never been characterised in DDR using the DT40 
cell system. We investigated the DDR of CP using 20 mutant cell lines 
that cover major DNA repair or tolerance pathways. Our results 
showed that a series of FANC-deficient cells were hypersensitive to CP 
metabolised with the S9 mix (activated CP), indicating that the FANC 
pathway is critical for repairing DNA damage caused by activated 
CP. CP has been used as a chemotherapeutic agent in the treatment 
of leukaemia and solid tumours for nearly 70 years (24). The ability 
of CP to induce interstrand crosslinks (ICLs) on DNA is key for its 
function and one that requires metabolic activation. Fanconi anaemia, 
a genetic disorder that results in sensitivity to ICLs (25–27), is caused 
by the mutation of one of at least 16 different genes. Although their 
functions have not been completely elucidated, there is substantial evi-
dence to suggest that these genes participate in a common pathway of 
ICL repair (28). Our finding is very consistent with these reports. It 
is also noteworthy that FANC-deficient DT40 cells were ~10-fold or 
more sensitive to CP in the presence of S9 than CP in the absence of 
metabolic activation (Supplemental Figure 1, available at Mutagenesis 
Online), which indicates that the preincubation method employed 
in this study worked well to generate genotoxic metabolites. These 
results also imply that the metabolic preactivation system could be 
useful for researchers to investigate not only genotoxicity but also the 
mechanism of action of a wide range of agents.
In addition, DT40 mutants lacking REV3 and RAD18 genes, 
which are associated with the translesion synthesis (TLS) pathway, 
showed severe toxicity in the presence of activated CP. Previous 
work demonstrated that mutants of the TLS polymerases REV1 
and Pol-ζ (a complex of REV3 and REV7) are exquisitely sensitive 
to cross-linking agents (29). It was also reported that suppression 
of REV3 sensitises drug-resistant lung tumours to chemotherapy, 
and suppression of REV1 inhibits both cisplatin- and CP-induced 
mutagenesis (30,31). The higher toxicity observed in REV3 and 
RAD18-deficient mutants compared to that seen in the parental 
DT40 cells is consistent with these reports. It is worthwhile to note 
that activated CP could produce mono adducts as well as intrastrand 
crosslinks. The high cellular toxicity in REV3, and RAD18-deficient 
mutants in the presence of activated CP could be partly due to the 
inability to bypass mono adducts (32).
The DDR assay focuses on cytotoxicity, but CP is known to 
induce MN as a marker of genotoxicity. MN induction was inves-
tigated in DT40 wild-type and CP-sensitive mutant cell lines. The 
results were analyzed by bench mark dose analysis software v2.5 
provided by the US EPA, which enables us to calculate PoD using 
several types of fitting models. The PoD concentrations in hypersen-
sitive mutant cell lines were lower than for the parental DT40 wild-
type cell lines, indicating that activated CP-derived DNA damage is 
repaired or tolerated by FANC and/or TLS pathways.
Overall, our DT40 cell-based DDR assay with metabolic acti-
vation could provide a valuable tool to elucidate the DNA dam-
age repair/tolerance pathways of a wide range of genotoxic agents. 
Although more chemicals need to be examined for further validation, 
this assay could be incorporated as part of the HTS-based bioassay 
such as Tox21 (33), which will enable us to evaluate chemicals in 
the presence and absence of metabolic activation. Our assay has the 
potential of broadening the range of chemicals and will greatly help 
in evaluating uncharacterised xenobiotics.
Supplementary data
Supplementary Table  1 and Figure  1 is available at Mutagenesis 
Online.
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